檢索結果 - Tadeusz Robak

Refine Results
  1. 1
    Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia

    Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia 由 Tadeusz Robak

    出版 2004
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

    Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospectiv... 由 Tadeusz Robak

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Pharmacogenomics of<i>MDR1</i>/<i>ABCB1</i>Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies

    Pharmacogenomics of<i>MDR1</i>/<i>ABCB1</i>Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies 由 Krzysztof Jamroziak, Tadeusz Robak

    出版 2004
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Safety and Tolerability of Antibody-Drug Conjugates in Cancer

    Safety and Tolerability of Antibody-Drug Conjugates in Cancer 由 Anna Wolska, Tadeusz Robak

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

    Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later 由 Paweł Robak, Tadeusz Robak

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

    Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives 由 Ewa Robak, Tadeusz Robak

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

    The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions 由 Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  8. 8
    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives

    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives 由 Iwona Hus, Bartosz Puła, Tadeusz Robak

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  9. 9
    Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need

    Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need 由 Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Toll-like receptors and their role in carcinogenesis and anti-tumor treatment

    Toll-like receptors and their role in carcinogenesis and anti-tumor treatment 由 Anna Wolska, Ewa Lech‐Marańda, Tadeusz Robak

    出版 2008
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  11. 11
    Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis

    Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis 由 Tadeusz Robak, A Gladalska, H Stępień, Ewa Robak

    出版 1998
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update

    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update 由 Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak

    出版 2024
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  13. 13
    Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

    Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases 由 Tadeusz Robak, Anna Korycka, Ewa Lech‐Marańda, Paweł Robak

    出版 2009
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  14. 14
    Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 由 Barbara Eichhorst, Martin Dreyling, Tadeusz Robak, Emili Montserrat, Michael Hallek

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 由 Tadeusz Robak, Estella Matutes, Daniel Catovsky, Pier Luigi Zinzani, Christian Buske

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus

    Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus 由 Agnieszka Klonowska-Szymczyk, Anna Wolska, Tadeusz Robak, Barbara Cebula‐Obrzut, Piotr Smolewski, Ewa Robak

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia 由 Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide th... 由 Pieter Sonneveld, Roman Hájek, Arnon Nagler, Andrew Spencer, Joan Bladé, Tadeusz Robak, Sen Hong Zhuang, Jean‐Luc Harousseau, Robert Z. Orlowski

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies 由 Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer, Emili Montserrat

    出版 2018
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  20. 20
    Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

    Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis 由 Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan‐Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: